The prevalence, distribution and impact of peripheral neuropathy among Danish patients with cancer – a population-based cross-sectional study

References

• Staff NP, Grisold A, Grisold W, et al. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol. 2017;81(6):772–781.
   PubMed Web of Science ®Google Scholar
• Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and Meta-analysis. Pain [Internet]. 2014;155(12):2461–2470.
   Google Scholar
• Eckhoff L, Knoop A, Jensen MB, et al. Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. Eur J Cancer [Internet]. 2015;51(3):292–300.
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol. 2020;38(28):3325–3348.
   PubMed Web of Science ®Google Scholar
• Starobova H, Vetter I. Pathophysiology of Chemotherapy-Induced peripheral neuropathy. Front Mol Neurosci. 2017;10:174.
   PubMed Web of Science ®Google Scholar
• McCrary JM, Goldstein D, Boyle F, et al.; IN FOCUS Delphi working party. Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and delphi survey. Support Care Cancer. 2017;25(11):3485–3493.
   PubMed Web of Science ®Google Scholar
• Molassiotis A, Cheng HL, Lopez V, et al. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer. 2019;19(1):19.
   PubMedGoogle Scholar
• Hanewinckel R, Drenthen J, Van Oijen M, et al. Prevalence of polyneuropathy in the general Middle-aged and elderly population. Neurology. 2016;87(18):1892–1898.
   PubMed Web of Science ®Google Scholar
• Stone JB, DeAngelis LM. Cancer-treatment-induced neurotoxicity-focus on newer treatments. Nat Rev Clin Oncol. 2016;13(2):92–105.
   PubMed Web of Science ®Google Scholar
• Smith DI, Tran HT, Poku J. Hemodynamic considerations in the pathophysiology of peripheral neuropathy. Blood Press - From bench to bed [internet]. InTech. 2018. Available from: http://www.intechopen.com/books/blood-pressure-from-bench-to-bed/hemodynamic-considerations-in-the-pathophysiology-of-peripheral-neuropathy.
   Google Scholar
• Groenvold M, Klee MC, Sprangers MAG, et al. Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. J Clin Epidemiol. 1997;50(4):441–450.
   PubMed Web of Science ®Google Scholar
• Esser P, Hartung TJ, Friedrich M, et al. The generalized anxiety disorder screener (GAD-7) and the anxiety module of the hospital and depression scale (HADS-A) as screening tools for generalized anxiety disorder among cancer patients. Psychooncology. 2018;27(6):1509–1516.
   PubMed Web of Science ®Google Scholar
• Pedersen SS, Mathiasen K, Christensen KB, et al. Psychometric analysis of the patient health questionnaire in danish patients with an implantable cardioverter defibrillator (the DEFIB-WOMEN study). J Psychosom Res. 2016;90:105–112.
   PubMed Web of Science ®Google Scholar
• Boren T, Ramey J. Thinking aloud: reconciling theory and practice. IEEE Trans Prof Commun. 2000;43(3):261–278.
   Google Scholar
• Le-Rademacher J, Kanwar R, Seisler D, et al. Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/alliance clinical trials. Support Care Cancer. 2017;25(11):3537–3544.
   PubMed Web of Science ®Google Scholar
• Kieffer JM, Postma TJ, van de Poll-Franse L, et al.; In Collaboration with the CI-PeriNomS Group. Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20). Qual Life Res. 2017;26(11):2999–3010.
   PubMed Web of Science ®Google Scholar
• Giesinger JM, Kieffer JM, Fayers PM, et al.; EORTC Quality of Life Group. Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust. J Clin Epidemiol. 2016;69:79–88.
   PubMed Web of Science ®Google Scholar
• Manea L, Gilbody S, McMillan D. Optimal cut-off score for diagnosing depression with the patient health questionnaire (PHQ-9): a Meta-analysis. CMAJ. 2012;184(3):E191–E196.
   PubMed Web of Science ®Google Scholar
• Spitzer RL, Kroenke K, Williams JBW, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–1097.
   PubMed Web of Science ®Google Scholar
• Arrieta J, Aguerrebere M, Raviola G, et al. Validity and utility of the patient health questionnaire (PHQ)-2 and PHQ-9 for screening and diagnosis of depression in rural Chiapas, Mexico: a Cross-Sectional study. J Clin Psychol. 2017;73(9):1076–1090.
   PubMed Web of Science ®Google Scholar
• Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B [Internet]. 1995;57(1):289–300.
   Google Scholar
• Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. New York: Lawrence Erlbaum Associates; 1988.
   Google Scholar
• Greenwald MK, Ruterbusch JJ, Beebe-Dimmer JL, et al. Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a medicare population. Cancer [Internet]. 2019;125(2):269–277.
   PubMed Web of Science ®Google Scholar
• Shah A, Hoffman EM, Mauermann ML, et al. Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort. J Neurol Neurosurg Psychiatry. 2018;89(6):636–641.
   PubMed Web of Science ®Google Scholar
• Chan A, Hertz DL, Morales M, et al. Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview. Support Care Cancer. 2019;27(10):3729–3737.
   PubMed Web of Science ®Google Scholar
• Ezendam NPM, Pijlman B, Bhugwandass C, et al. Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry. Gynecol Oncol. 2014;135(3):510–517.
   PubMed Web of Science ®Google Scholar
• Bulls HW, Hoogland AI, Kennedy B, et al. A longitudinal examination of associations between age and chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer. Gynecol Oncol [Internet]. 2019;152(2):310–315.
   PubMed Web of Science ®Google Scholar
• Molassiotis A, Cheng HL, Leung KT, et al. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav. 2019;9(6):1–10.
   Web of Science ®Google Scholar
• Nyrop KA, Deal AM, Reeder‐Hayes KE, et al. Patient‐reported and clinician‐reported chemotherapy‐induced peripheral neuropathy in patients with early breast cancer: Current clinical practice. Cancer [Internet]. 2019;125(17):2945–2954.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Till C, Wright JD, et al. Comorbidities and risk of Chemotherapy-Induced peripheral neuropathy among participants 65 years or older in southwest oncology group clinical trials. J Clin Oncol. 2016;34(25):3014–3022.
   PubMed Web of Science ®Google Scholar
• Simon NB, Danso MA, Alberico TA, et al. The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice. Qual Life Res. 2017;26(10):2763–2772.
   PubMed Web of Science ®Google Scholar
• Bonhof CS, Trompetter HR, Vreugdenhil G, et al. Painful and non-painful chemotherapy-induced peripheral neuropathy and quality of life in colorectal cancer survivors: results from the population-based PROFILES registry. Support Care Cancer. 2020;28(12):5933–5941.
   PubMed Web of Science ®Google Scholar
• Smith EML, Zanville N, Kanzawa-Lee G, et al. Rasch model-based testing of the european organisation for research and treatment of cancer (EORTC) quality of life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data. Support Care Cancer. 2019;27(7):2599–2608.
   PubMed Web of Science ®Google Scholar
• Knudsen AK, Hotopf M, Skogen JC, et al. The health status of nonparticipants in a population-based health study: the Hordaland Health Study. Am J Epidemiol. 2010;172(11):1306–1314.
   PubMed Web of Science ®Google Scholar
• Bao T, Basal C, Seluzicki C, et al. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat. 2016;159(2):327–333.
   PubMed Web of Science ®Google Scholar
• Alberti P, Rossi E, Cornblath DR, et al.; CI-PeriNomS Group. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: Two sides of the same coin. Ann Oncol. 2014;25(1):257–264.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Park SB, Islam B, et al.; Toxic Neuropathy Consortium (TNC). Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings. J Neurol Neurosurg Psychiatry. 2019;90(12):1361–1369.
   PubMed Web of Science ®Google Scholar
• Coumbe BGT, Groarke JD. Cardiovascular autonomic dysfunction in patients with cancer. Curr Cardiol Rep. 2018;20(8):10–17.
   PubMed Web of Science ®Google Scholar
• Gewandter JS, Brell J, Cavaletti G, et al. Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations. Neurology. 2018;91(9):403–413.
   PubMed Web of Science ®Google Scholar